Business
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
HENDERSON, Nev., August 20, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor mee
About this update from Zura Bio Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/b4250b120f9f4fb464ddec65298cd25b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s7uIbGW1sSTim_pXz1XSKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b4250b120f9f4fb464ddec65298cd25b","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JWhalre4cJKgMS7oO7JMDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/b4250b120f9f4fb464ddec65298cd25b","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HENDERSON, Nev., August 20, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day.","length":559,"tagName":"p"},{"type":"text","content":"A live webcast of the presentation will be available in the Investors section of the Company’s website under News & Events. A replay will remain archived for at least 30 days.","length":179,"tagName":"p"},{"type":"text","content":"ABOUT ZURA BIO","length":14,"tagName":"p"},{"type":"text","content":"Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. The Company’s pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.","length":368,"tagName":"p"},{"type":"text","content":"Zura Bio’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and to...